Navigation Links
Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Date:5/12/2008

t of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to be Featured on Wallst.net
5. Synvista Therapeutics to Present at the BIO InvestorForum 2007
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... knowingly misrepresented the ... company to ... filed a,proposed class-action lawsuit on behalf of CellCyte Genetics Corporation,(OTC ... and chief executive officer Gary A.,Reys, background, causing company stocks ...
... SAN DIEGO, Jan. 18 The San Diego ... has received the,highest score in three of four ... on Part I of the Major Facilities Grant,Application., ... earned scores of,99 for basic research and discovery, ...
... objects to implications in a New York Times article ... clinical,trials., The story, based on a separate article ... and Lilly as high-profile examples of how the,industry purportedly ... story inaccurate when it comes to Prozac -- the ...
Cached Biology Technology:Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 2SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4
(Date:4/15/2014)... BETHESDA, Md. (April 15, 2014) The American ... 2014 award winners. All awards will be presented ... San Diego Marriott Hotel on Tuesday, April 29th at ... Biology (EB). , The 2014 award winners ... Jeffrey Laitman, PhD, of the Icahn School of ...
(Date:4/15/2014)... it has become clear that the genetic code ... addition to the well-known building blocks adenine, cytosine, ... important role. Scientists now assume that the newly ... layer of information that extends and complements the ... umlauts that extend the standard alphabet," explained Professor ...
(Date:4/14/2014)... 32-year study of subarctic forest moths in Finnish Lapland ... climate change on animals and plants because much of ... analyzed populations of 80 moth species and found that ... throughout the study period, from 1978 to 2009. During ... rose 3.5 degrees Fahrenheit, and winter precipitation increased as ...
Breaking Biology News(10 mins):American Association of Anatomists 2014 award winners 2German Research Foundation approves new priority program in the life sciences 2Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3
... why people who are able to easily and accurately recall ... with word recall or remembering the day’s current events. They ... out information and increasing the time it takes for new ... the Proceedings of the National Academy of Sciences (March 13, ...
... years and more than 2,000 samples after researchers at ... gene-chip technology called chromosomal microarray analysis to look for ... is remarkably sensitive in detecting abnormalities in individual chromosomes, ... the journal Public Library of Science ONE. , "Chromosomal ...
... state of others by looking at their eyes, contrary ... has found. , In findings that contradict previous studies, ... state based on that person’s eyes. Autistic children have ... mental states based on facial expressions, especially expressions around ...
Cached Biology News:New research shows why too much memory may be a bad thing 2Chromosomal microarray analysis proves accurate 2'The eyes have it' -- Autism research yields surprising results 2
Quartz-Halogen, 100 W, High Intensity...
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
...
Biology Products: